Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis-Reference-Cited by-同舟云学术

Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis

Published:2024-08-26 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Poveda-García Andrea,Ruiz Estela,Moreno María José,Español Ignacio,Sánchez-Salinas Andrés,García-Hernández Ana María^ORCID,Blanquer Miguel^ORCID,Martínez Inmaculada,Sánchez-Villalobos María,García Garay María Carmen,Salido Eduardo,Heredia Ángela,Navarro-Almenzar Begoña,Monserrat Jorge,Sánchez-Salas José Antonio,Martínez-Mellado Antonio José,Minguela Alfredo,Campillo José Antonio,López-Hernández Ruth,Galián José Antonio^ORCID,Moraleda José M.^ORCID,Roldán Vanessa,Cabañas Valentín^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02404-1.pdf

Reference10 articles.

1. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–96.

2. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, et al. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022;12:47.

3. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol J Am Soc Clin Oncol. 2007;25:2434–41.

4. Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguiñano JM, et al. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). Leuk Lymphoma. 2022;63:3438–47.

5. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol J Am Soc Clin Oncol. 2019;37:589–97.